Last updated: February 20, 2026
What is the drug associated with NDC 67877-0732?
NDC 67877-0732 is associated with Eptinezumab, marketed under the brand name Vyepti. It is a monoclonal antibody developed to prevent migraines in adult patients.
Market overview
Approved indications and regulatory status
- Indication: Chronic and episodic migraine prevention.
- FDA approval date: February 21, 2020.
- Regulatory status: Marketed by Lundbeck.
Market size and growth
The migraine prevention market has seen steady growth driven by increased awareness and higher prescribing rates.
- Estimated global migraine treatment market size in 2022: approximately $4 billion.
- Compound annual growth rate (CAGR) from 2022 to 2027: projected at 8%–10%.
Competitive landscape
Key competitors include:
| Drug |
Mechanism |
Approvals |
Annual US sales (2022) |
Pricing (per dose) |
| Erenumab (Aimovig) |
CGRP receptor monoclonal antibody |
2018 |
~$600 million |
$575–$650 |
| Fremanezumab (Ajovy) |
CGRP monoclonal antibody |
2018 |
~$330 million |
$575–$650 |
| Galcanezumab (Emgality) |
CGRP monoclonal antibody |
2018 |
~$450 million |
$575–$650 |
| Eptinezumab (Vyepti) |
CGRP monoclonal antibody |
2020 |
~$150 million |
~$600–$650 per dose |
Sales trajectory
Vyepti's sales are outperforming initial forecasts but still trail behind initial market leaders. The product's growth hinges on:
- Physician adoption.
- Patient access programs.
- Market penetration in hospital and infusion settings.
Price analysis and projections
Current pricing structure
- Per dose: Approximately $600–$650.
- Dosing schedule: Once every three months (quarterly infusion), differing from monthly subcutaneous options.
- Annual treatment cost: Approximately $2,400–$2,600 per patient.
Price trends
While initial pricing aligns with other monoclonal antibodies targeting migraine, future pricing may hinge on:
- Competition from similar drugs.
- Payer negotiations.
- Manufacturing costs.
Future price projections
Assuming market expansion and competitive pressures, projections include:
| Year |
Expected price per dose |
Expected annual cost per patient |
Comments |
| 2023 |
$600 |
$2,400 |
Stable, barring regulatory or patent changes |
| 2025 |
$550–$600 |
$2,200–$2,400 |
Potential discounts for payer negotiations |
| 2027 |
$500–$550 |
$2,000–$2,200 |
Increased competition could pressure prices |
Pricing could decrease by approximately 10%–15% over the next five years as biosimilar or alternative therapies emerge and payer strategies evolve.
Key market risks
- Patent expiry: Patents for Vyepti are valid until at least 2032, delaying biosimilar entry.
- Regulatory pressures: Potential for pricing regulations particularly in European markets.
- Market penetration: Slower uptake due to existing established therapies or patient preference.
Regulatory and reimbursement considerations
- FDA: Approved in 2020, with no significant post-marketing restrictions.
- CMS and private insurers: Reimbursement policies favor infusion therapies within hospital settings, affecting sales and pricing.
Summary
Vyepti (NDC 67877-0732) is a relatively new entrant in the migraine prevention space. Its current price remains stable at around $600 per dose, with an annual patient cost exceeding $2,400. Market growth is expected to continue at a CAGR of roughly 8–10%, but competitive and regulatory pressures may influence future prices downward.
Key Takeaways
- Vyepti's market share remains limited compared to oral or subcutaneous monoclonal antibodies.
- Pricing is comparable with other CGRP inhibitors but benefits from less frequent dosing.
- Market growth projections depend heavily on physician adoption and reimbursement policies.
- Price reductions are likely over the next five years, driven by intensified competition and biosimilar development.
- Patent protection is in place through at least 2032, delaying biosimilar competition.
FAQs
1. How does Vyepti's dosing schedule compare to other migraine prevention drugs?
Vyepti is administered via infusion every three months, reducing patient burden relative to monthly subcutaneous options like Aimovig, Fremanezumab, and Emgality.
2. What are the primary drivers of growth for Vyepti?
Market expansion relies on increased physician familiarity, reimbursement access, and hospital infusion center adoption.
3. Is Vyepti more cost-effective than alternative therapies?
Cost-effectiveness depends on individual patient response, but its quarterly infusion schedule may reduce overall treatment costs compared to monthly injections.
4. When will biosimilars for Vyepti likely enter the market?
Patent protections through at least 2032 delay biosimilar entry; development timelines for biosimilars suggest market entry may occur post-2032.
5. What regulatory factors could impact Vyepti's pricing?
Regulatory initiatives aimed at drug price transparency or price caps could pressure manufacturer pricing strategies.
References
[1] Market data from IQVIA, 2022.
[2] FDA approval documents for Vyepti, 2020.
[3] Industry analysis reports, 2022–2023.
